TOKYO, Mar 19 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) reported a revenue decline of ¥28 million for the fiscal year ending December 2025 compared to ¥31 million in the previous year due to the strong yen impact despite income from Transposon Co.
Research and development expenses increased to ¥13.50 billion from ¥12.03 billion. lower operating profit widened to ¥352.5 billion from ¥2.024 billion, while lower net profit grew to ¥2.058 billion from ¥2.051 billion.
For the fiscal year ending December 2026, the company refrained from providing earnings forecasts citing uncertainties such as regulatory approval timelines for OBP-301, pricing decisions, sales launch timing, and milestone payments related to corporate actions involving T Corp. In its pipeline update, Oncolys highlighted ongoing clinical trials for OBP-301, a tumor-dissolving adenovirus, targeting esophageal cancer and aiming for approval based on Phase 2 trial data.
The company also noted plans to collaborate with FujiFilm Toyama Chemical to estimate future supply volumes post-price standard inclusion for OBP-301.
🟡 Confidence: Standard AI-translated content.